Finerenone is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).
来自FDA,2022.09
This article analyzes the clinical application and economic cost of finerenone.What are the suitable populations for finerenone?The use of this drug should be strictly in accordanc···【more】
Article source:Lucius LaosRelease date:2025-04-15Recommended:37
According to the treatment needs of patients with specific chronic diseases, the application value of finerenone has gradually attracted attention.What diseases is finerenone suita···【more】
Article source:Lucius LaosRelease date:2025-04-15Recommended:33
In view of the application value and clinical practice of finerenone, this article reviews the key information.What are the indications for finerenoneThis drug has shown a unique r···【more】
Article source:Lucius LaosRelease date:2025-04-14Recommended:41
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: